Developer docs
API playgroundTry for free, no card

Search company profiles

Allergy Therapeutics

Full company profile

uuid0029eyh

Namestring
Allergy Therapeutics
Legal namestring
Allergy Therapeutics PLC
Company typeenum
Public
Founded yearint
1999
Descriptiontext

Allergy Therapeutics plc (AIM: AGY) is a UK-based specialty pharmaceutical company developing and commercialising allergy immunotherapy vaccines for the treatment and prevention of allergic disorders. Founded in 1934 (with the current corporate entity listed on AIM in 2004) and headquartered in Worthing with 600+ employees, the company serves patients with grass, tree and house dust mite allergies and, in development, peanut allergy. Its core technology combines a proprietary virus-like particle (VLP) platform with biodegradable aluminium-free adjuvant systems developed since the 1970s, allowing shorter-course regimens of 4-6 injections over 3-5 weeks versus 50-100 injections for many conventional immunotherapies.

The commercial portfolio is anchored by Grassmuno, the first new subcutaneous grass pollen immunotherapy approved in Germany in 20 years, which launched in January 2026 and drove 7% H1 FY2026 revenue growth to £36.3m. The pipeline is led by VLP Peanut, whose Phase I/IIa PROTECT trial reported statistically significant reductions in basophil sensitivity (376% for peanut, p=0.003; 489% for Ara h2, p=0.04) and supports progression into Phase IIb. Manufacturing is conducted at the 11,000m2 Worthing facility and at Alcalá de Henares in Spain under GMP/GDP/GCP compliance.

Revenue is generated almost entirely through B2B sales of vaccine products via 9 wholly-owned European subsidiaries (UK, Germany, Austria, Switzerland, Italy, Netherlands, Spain and others) plus distribution agreements in 3 additional countries, with products ultimately dispensed through hospitals and pharmacies. The company reported £55.0m revenue, £(12.8)m operating loss excluding R&D and £(40.1)m net loss for FY2024, while securing £55m in warrant proceeds and a £50m loan facility in October 2025 alongside shareholder approval to issue up to 610m new shares ahead of a potential Hong Kong dual primary listing. A mandatory cash offer from ZQ Capital's SkyGem vehicle introduces a going-private scenario that may redefine the corporate trajectory.

Short descriptiontext

Allergy Therapeutics plc is a UK-listed specialty biopharma (AIM: AGY) developing and commercialising short-course aluminium-free allergy immunotherapy vaccines across 9 European countries, with Grassmuno recently launched in Germany and a VLP Peanut programme in clinical development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersWorthing, United Kingdom
HQ citystring
Worthing
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices9 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
allergy immunotherapy, allergen vaccines, subcutaneous immunotherapy, biodegradable adjuvants, virus-like particle vaccines
Industry6 codes
PRIMARYHLAAAEAI
Allergy Immunotherapy Biologics (allergen extracts, desensitization)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAKAAAF
Allergen Immunotherapy (SCIT/SLIT) Services
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAALAK
Autoimmune & Allergy Diagnostics
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Allergy Immunotherapy Vaccines
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Product Sales (Immunotherapy Vaccines)
TypeOne Time License
Description

Revenue generated from the sale of allergy immunotherapy vaccines across European markets. The company reported £36.3 million revenue for H1 FY2026 (7% YoY growth) and £55.0 million for FY2024. Products include Grassmuno (subcutaneous grass pollen immunotherapy) launched in Germany in January 2026.

allergytherapeutics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Grassmuno
Description

Subcutaneous grass pollen immunotherapy product approved in Germany in December 2025, representing the first new product launch in Germany in 20 years.

m.in.investing.com
+1 more record
Core offering1 text field

Allergy Therapeutics is a European-based speciality pharmaceutical company that develops, manufactures, and commercialises allergy immunotherapy vaccines. Its portfolio includes subcutaneous immunotherapies for grass pollen (Grassmuno), tree pollen, and house dust mite allergies, all formulated with proprietary aluminium-free, biodegradable adjuvants. The company is also advancing a virus-like particle (VLP) peanut allergy vaccine through clinical development, with shorter-course dosing regimens (4–6 injections over 3–5 weeks) compared with conventional therapies requiring 50–100 injections.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 7% revenue growth to £36.3 million in H1 FY2026
+3 more records
Product overview1 text field

Allergy Therapeutics is a biotechnology company offering a portfolio of allergy immunotherapy products and vaccines. The core portfolio includes Grassmuno (subcutaneous grass pollen immunotherapy approved in Germany in 2025/2026) and VLP Peanut (a peanut allergy vaccine in clinical development). The company also manufactures and sells immunotherapy vaccines for grass, tree, and house dust mite allergies across nine major European countries. All products feature aluminium-free, biodegradable adjuvants and are designed for shorter treatment courses (4-6 injections over 3-5 weeks) compared to alternative therapies requiring 50-100 injections.

Product and service3 records
1Grassmuno
CategoryAllergy Immunotherapy Vaccine
Description

A subcutaneous grass pollen immunotherapy vaccine offering a short-course regimen of 4–6 injections over 3–5 weeks. Approved in Germany in December 2025 and launched in January 2026 for the treatment of grass pollen allergy in adults, dispensed through hospitals and pharmacies and prescribed by healthcare professionals.

2Allergy Immunotherapy Vaccines (Grass, Tree, House Dust Mite)
CategoryAllergy Immunotherapy Vaccine
Description

A portfolio of subcutaneous allergen-specific immunotherapy vaccines covering grass pollen, tree pollen and house dust mite allergies. All formulations use natural biodegradable, aluminium-free adjuvants and are intended for prescription and administration by allergists and immunologists.

3VLP Peanut
CategoryAllergy Immunotherapy Vaccine (In Development)
Description

A peanut allergy vaccine based on proprietary virus-like particle (VLP) technology currently in clinical development. The PROTECT Phase I/IIa trial showed favourable safety and statistically significant efficacy biomarkers, with the company preparing a Phase IIb trial.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Healthcare Facilities and Pharmacies (unspecified)
Strategic tierCoreTypeOthers
Description

The company distributes its immunotherapy vaccines through hospitals and pharmacies across European markets. The Market Support team serves as the link between manufacturing and these healthcare outlets, dealing with customer queries and ensuring products are delivered on time.

allergytherapeutics.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ALK-Abelló is the world's largest allergy immunotherapy company, offering subcutaneous and sublingual treatments for grass, tree, mite and other allergies. It is the most direct comparable to Allergy Therapeutics given its overlapping product portfolio, European commercial footprint, and pipeline focus on allergy vaccines.

TypeDirect peer
Description

HAL Allergy is a European allergy immunotherapy specialist offering diagnostic and therapeutic products for pollen, mite and venom allergies. It is a direct peer through its European footprint, comparable subcutaneous immunotherapy portfolio and HCP-driven commercial approach.

TypeEmerging player
Description

Aimmune, a Nestlé Health Science subsidiary, develops and commercializes Palforzia, an oral immunotherapy for peanut allergy. It is an emerging competitor to Allergy Therapeutics' VLP Peanut program, addressing the same food allergy market with a different mechanism and delivery format.

TypeBroad incumbent
Description

Sanofi operates a large respiratory and allergy portfolio including Dupixent and OTC allergy brands. It is a broad incumbent competing in the overall allergy treatment market, particularly relevant if it expands into food allergy or immunotherapy adjacencies.

TypeOthers
Description

Thermo Fisher's Phadia division is a global leader in allergy diagnostics (ImmunoCAP), supplying the testing infrastructure used by allergists before prescribing immunotherapy. It is an adjacent ecosystem player rather than a direct competitor but is highly relevant to the same HCP and patient workflow.

TypeEmerging player
Description

DBV Technologies is developing Viaskin, a patch-based epicutaneous immunotherapy platform targeting peanut and other food allergies. It is an emerging peer competing in the same peanut allergy space as VLP Peanut, with a differentiated non-injection delivery mechanism.

TypeEmerging player
Description

Revolo Biotherapeutics is a clinical-stage biotech developing immune-modulating therapies for allergic and autoimmune diseases. It represents an emerging peer in the broader allergy immunology space that may compete with or complement Allergy Therapeutics' pipeline expansion.

TypeDirect peer
Description

Stallergenes Greer is a global specialty biopharmaceutical company focused on allergy immunotherapy, with subcutaneous and sublingual products sold across Europe and the US. Its product mix, allergen extract technology and HCP-facing commercial model directly parallel Allergy Therapeutics' business.

TypeDirect peer
Description

Inmunotek, the merged entity including Leti Pharma, develops and markets allergy immunotherapy and immunology products across Europe and Latin America. It is a direct peer given its overlapping allergen-specific immunotherapy portfolio and European commercial reach.

TypeBroad incumbent
Description

GSK is a global biopharma with a major respiratory and allergy franchise (e.g., Nucala, Trelegy) and broad OTC allergy offerings. It competes with Allergy Therapeutics in the wider allergy/respiratory treatment market but does not specialize in subcutaneous allergen-specific immunotherapy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Allergy Therapeutics

Allergy Immunotherapy Vaccinesallergytherapeutics.com

Allergy Therapeutics plc is a UK-listed specialty biopharma (AIM: AGY) developing and commercialising short-course aluminium-free allergy immunotherapy vaccines across 9 European countries, with Grassmuno recently launched in Germany and a VLP Peanut programme in clinical development.

What Allergy Therapeutics does

Allergy Therapeutics plc (AIM: AGY) is a UK-based specialty pharmaceutical company developing and commercialising allergy immunotherapy vaccines for the treatment and prevention of allergic disorders. Founded in 1934 (with the current corporate entity listed on AIM in 2004) and headquartered in Worthing with 600+ employees, the company serves patients with grass, tree and house dust mite allergies and, in development, peanut allergy. Its core technology combines a proprietary virus-like particle (VLP) platform with biodegradable aluminium-free adjuvant systems developed since the 1970s, allowing shorter-course regimens of 4-6 injections over 3-5 weeks versus 50-100 injections for many conventional immunotherapies.

The commercial portfolio is anchored by Grassmuno, the first new subcutaneous grass pollen immunotherapy approved in Germany in 20 years, which launched in January 2026 and drove 7% H1 FY2026 revenue growth to £36.3m. The pipeline is led by VLP Peanut, whose Phase I/IIa PROTECT trial reported statistically significant reductions in basophil sensitivity (376% for peanut, p=0.003; 489% for Ara h2, p=0.04) and supports progression into Phase IIb. Manufacturing is conducted at the 11,000m2 Worthing facility and at Alcalá de Henares in Spain under GMP/GDP/GCP compliance.

Revenue is generated almost entirely through B2B sales of vaccine products via 9 wholly-owned European subsidiaries (UK, Germany, Austria, Switzerland, Italy, Netherlands, Spain and others) plus distribution agreements in 3 additional countries, with products ultimately dispensed through hospitals and pharmacies. The company reported £55.0m revenue, £(12.8)m operating loss excluding R&D and £(40.1)m net loss for FY2024, while securing £55m in warrant proceeds and a £50m loan facility in October 2025 alongside shareholder approval to issue up to 610m new shares ahead of a potential Hong Kong dual primary listing. A mandatory cash offer from ZQ Capital's SkyGem vehicle introduces a going-private scenario that may redefine the corporate trajectory.

Allergy Therapeutics firmographics

Firmographics
Name
Allergy Therapeutics
Legal name
Allergy Therapeutics PLC
Website
https://allergytherapeutics.com
Company type
Public
Founded year
1999
Operating status
Operating
Headcount range
251–500 employees
Short description
Allergy Therapeutics plc is a UK-listed specialty biopharma (AIM: AGY) developing and commercialising short-course aluminium-free allergy immunotherapy vaccines across 9 European countries, with Grassmuno recently launched in Germany and a VLP Peanut programme in clinical development.
Ownership category
akta.pro rank

Allergy Therapeutics industry classification

Industry
Product category
Allergy Immunotherapy Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAEAI
Allergy Immunotherapy Biologics (allergen extracts, desensitization)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAKAAAF
Allergen Immunotherapy (SCIT/SLIT) Services
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAALAK
Autoimmune & Allergy Diagnostics

Keywords

  • Allergy immunotherapy
  • Allergen vaccines
  • Subcutaneous immunotherapy
  • Biodegradable adjuvants
  • Virus-like particle vaccines

Where Allergy Therapeutics is headquartered

Location

Headquarters

HQ city
Worthing
HQ country
United Kingdom
HQ region
Europe

Offices9 records

Markets served

Allergy Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

  1. Product Sales (Immunotherapy Vaccines): Revenue generated from the sale of allergy immunotherapy vaccines across European markets. The company reported £36.3 million revenue for H1 FY2026 (7% YoY growth) and £55.0 million for FY2024. Products include Grassmuno (subcutaneous grass pollen immunotherapy) launched in Germany in January 2026.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Allergy Therapeutics product offering

Product offering

Core offering

Allergy Therapeutics is a European-based speciality pharmaceutical company that develops, manufactures, and commercialises allergy immunotherapy vaccines. Its portfolio includes subcutaneous immunotherapies for grass pollen (Grassmuno), tree pollen, and house dust mite allergies, all formulated with proprietary aluminium-free, biodegradable adjuvants. The company is also advancing a virus-like particle (VLP) peanut allergy vaccine through clinical development, with shorter-course dosing regimens (4–6 injections over 3–5 weeks) compared with conventional therapies requiring 50–100 injections.

Product overview

Allergy Therapeutics is a biotechnology company offering a portfolio of allergy immunotherapy products and vaccines. The core portfolio includes Grassmuno (subcutaneous grass pollen immunotherapy approved in Germany in 2025/2026) and VLP Peanut (a peanut allergy vaccine in clinical development). The company also manufactures and sells immunotherapy vaccines for grass, tree, and house dust mite allergies across nine major European countries. All products feature aluminium-free, biodegradable adjuvants and are designed for shorter treatment courses (4-6 injections over 3-5 weeks) compared to alternative therapies requiring 50-100 injections.

Differentiator

Problem solved

Functional benefit

Brands

  • Grassmuno: Subcutaneous grass pollen immunotherapy product approved in Germany in December 2025, representing the first new product launch in Germany in 20 years.
  • VLP Peanut

Products and services

  • Grassmuno A subcutaneous grass pollen immunotherapy vaccine offering a short-course regimen of 4–6 injections over 3–5 weeks. Approved in Germany in December 2025 and launched in January 2026 for the treatment of grass pollen allergy in adults, dispensed through hospitals and pharmacies and prescribed by healthcare professionals.
  • Allergy Immunotherapy Vaccines (Grass, Tree, House Dust Mite) A portfolio of subcutaneous allergen-specific immunotherapy vaccines covering grass pollen, tree pollen and house dust mite allergies. All formulations use natural biodegradable, aluminium-free adjuvants and are intended for prescription and administration by allergists and immunologists.
  • VLP Peanut A peanut allergy vaccine based on proprietary virus-like particle (VLP) technology currently in clinical development. The PROTECT Phase I/IIa trial showed favourable safety and statistically significant efficacy biomarkers, with the company preparing a Phase IIb trial.

Quantifiable outcome

  • 7% revenue growth to £36.3 million in H1 FY2026
  • +3 more outcomes

Companies that use Allergy Therapeutics

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Allergy Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Allergy Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Healthcare Facilities and Pharmacies (unspecified)coreOthersThe company distributes its immunotherapy vaccines through hospitals and pharmacies across European markets. The Market Support team serves as the link between manufacturing and these healthcare outlets, dealing with customer queries and ensuring products are delivered on time.

Scale indicators9 records

Recent moves8 records

Expansion highlights5 records

Allergy Therapeutics competitors and assessment

Company assessment

Direct peers

  • ALK-Abelló: ALK-Abelló is the world's largest allergy immunotherapy company, offering subcutaneous and sublingual treatments for grass, tree, mite and other allergies. It is the most direct comparable to Allergy Therapeutics given its overlapping product portfolio, European commercial footprint, and pipeline focus on allergy vaccines.
  • HAL Allergy: HAL Allergy is a European allergy immunotherapy specialist offering diagnostic and therapeutic products for pollen, mite and venom allergies. It is a direct peer through its European footprint, comparable subcutaneous immunotherapy portfolio and HCP-driven commercial approach.
  • Stallergenes Greer: Stallergenes Greer is a global specialty biopharmaceutical company focused on allergy immunotherapy, with subcutaneous and sublingual products sold across Europe and the US. Its product mix, allergen extract technology and HCP-facing commercial model directly parallel Allergy Therapeutics' business.
  • Inmunotek (Leti Pharma): Inmunotek, the merged entity including Leti Pharma, develops and markets allergy immunotherapy and immunology products across Europe and Latin America. It is a direct peer given its overlapping allergen-specific immunotherapy portfolio and European commercial reach.

Emerging players

  • Aimmune Therapeutics (Nestlé Health Science): Aimmune, a Nestlé Health Science subsidiary, develops and commercializes Palforzia, an oral immunotherapy for peanut allergy. It is an emerging competitor to Allergy Therapeutics' VLP Peanut program, addressing the same food allergy market with a different mechanism and delivery format.
  • DBV Technologies: DBV Technologies is developing Viaskin, a patch-based epicutaneous immunotherapy platform targeting peanut and other food allergies. It is an emerging peer competing in the same peanut allergy space as VLP Peanut, with a differentiated non-injection delivery mechanism.
  • Revolo Biotherapeutics: Revolo Biotherapeutics is a clinical-stage biotech developing immune-modulating therapies for allergic and autoimmune diseases. It represents an emerging peer in the broader allergy immunology space that may compete with or complement Allergy Therapeutics' pipeline expansion.

Broad incumbents

  • Sanofi: Sanofi operates a large respiratory and allergy portfolio including Dupixent and OTC allergy brands. It is a broad incumbent competing in the overall allergy treatment market, particularly relevant if it expands into food allergy or immunotherapy adjacencies.
  • GSK (GlaxoSmithKline): GSK is a global biopharma with a major respiratory and allergy franchise (e.g., Nucala, Trelegy) and broad OTC allergy offerings. It competes with Allergy Therapeutics in the wider allergy/respiratory treatment market but does not specialize in subcutaneous allergen-specific immunotherapy.

Others

  • Thermo Fisher Scientific (Phadia): Thermo Fisher's Phadia division is a global leader in allergy diagnostics (ImmunoCAP), supplying the testing infrastructure used by allergists before prescribing immunotherapy. It is an adjacent ecosystem player rather than a direct competitor but is highly relevant to the same HCP and patient workflow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Allergy Therapeutics social profiles

Digital presence

Allergy Therapeutics compliance and trust

Trust signal

Compliance4 records

Allergy Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Allergy Therapeutics leadership team

Management profile

Number of profiles

Profiles11 records

Allergy Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Allergy Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Allergy Therapeutics M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Allergy Therapeutics

What does Allergy Therapeutics do?

Allergy Therapeutics is a European-based speciality pharmaceutical company that develops, manufactures, and commercialises allergy immunotherapy vaccines. Its portfolio includes subcutaneous immunotherapies for grass pollen (Grassmuno), tree pollen, and house dust mite allergies, all formulated with proprietary aluminium-free, biodegradable adjuvants. The company is also advancing a virus-like particle (VLP) peanut allergy vaccine through clinical development, with shorter-course dosing regimens (4–6 injections over 3–5 weeks) compared with conventional therapies requiring 50–100 injections.

Is Allergy Therapeutics a public or private company?

Allergy Therapeutics is a public company. It is classified as public and is currently operating.

When was Allergy Therapeutics founded?

Allergy Therapeutics was founded in 1999. It employs 251 to 500 people.

Where is Allergy Therapeutics based?

Allergy Therapeutics is headquartered in Worthing, United Kingdom, in the Europe region.

How does Allergy Therapeutics make money?

One revenue line is on record: product Sales (Immunotherapy Vaccines).

Who are Allergy Therapeutics's main competitors?

Direct peers on record are ALK-Abelló, HAL Allergy, Stallergenes Greer and Inmunotek (Leti Pharma). Emerging players are Aimmune Therapeutics (Nestlé Health Science), DBV Technologies and Revolo Biotherapeutics. Broad incumbents are Sanofi and GSK (GlaxoSmithKline). Thermo Fisher Scientific (Phadia) is listed as an others.

Does Allergy Therapeutics have an API?

No public API is recorded for Allergy Therapeutics.

What industry is Allergy Therapeutics in?

Allergy Therapeutics's product category is Allergy Immunotherapy Vaccines. Its primary akta.pro industry code is HLAAAEAI, Allergy Immunotherapy Biologics (allergen extracts, desensitization), with a secondary code of HLAKAAAF, Allergen Immunotherapy (SCIT/SLIT) Services. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingAllergy Therapeutics Announces Annual General MeetingAllergy Therapeutics will hold its annual general meeting on December 14, 2026, at DLA Piper's London offices. Shareholders will vote on canceling AIM trading and re-registering as a private limited company, with cancellation expected December 22, 2026 and re-registration targeted for the week beginning January 11, 2027. SkyGem and Southern Fox, holding 87.98% of issued shares, intend to support both proposals.InvestegateAudited Preliminary Results and Annual ReportAllergy Therapeutics reported audited revenue of £59.9m for the year to 30 June 2026, up 9% from £55.0m, with H2 growth exceeding 12% after Grassmuno's launch. Adjusted EBITDA loss widened to £14.9m, and shareholder loans were repaid in full. The company expects strong revenue growth in the year to 30 June 2027.BusinessCloudAllergy Therapeutics AIMs to go private… then list in Hong KongAllergy Therapeutics plans to de-list from London's AIM and list in Hong Kong, requiring 75% shareholder approval at its AGM. The board cites high AIM costs and a 71% share price drop this year. The company will offer a matched bargain facility to shareholders.InvestegateProposed Cancellation of AdmissionAllergy Therapeutics announced on 3 November 2026 its intention to propose cancelling admission of its ordinary shares to AIM and re-registering as a private limited company. The proposal requires 75% shareholder approval, and the company plans to explore a primary listing on the Hong Kong Stock Exchange.AdvfnAllergy Therapeutics PLC Proposed Cancellation of AdmissionAllergy Therapeutics proposed cancelling its AIM listing and re-registering as a private company, with the move to be voted on at its annual general meeting. The company intends to explore a primary listing on the Hong Kong Stock Exchange in due course.Markets DailyAllergy Therapeutics (LON:AGY) Hits New 12-Month Low – Here’s What HappenedAllergy Therapeutics shares hit a new 52-week low on Tuesday, trading as low as GBX 4.50 and closing at GBX 4.80. The company's market cap is £284.96 million, with a P/E ratio of -4.64 and a beta of 0.83.Markets DailyAllergy Therapeutics (LON:AGY) Hits New 12-Month Low – What’s Next?Allergy Therapeutics' stock hit a new 52-week low at GBX 5 during mid-day trading on Wednesday, with a volume of 45,843 shares. The company's market capitalization is £343.22 million, and its debt-to-equity ratio is 629.58. The stock's 50-day moving average is GBX 6.02, while the 200-day average is GBX 8.61.Ticker ReportAllergy Therapeutics (LON:AGY) Sets New 52-Week Low – Time to Sell?Allergy Therapeutics plc stock hit a new 52-week low of GBX 5 on Wednesday, down from its previous close of GBX 5.25, with 140,799 shares trading hands. The stock has declined significantly below its 50-day moving average of GBX 6.98 and 200-day moving average of GBX 9.36, reflecting a sustained downward trend. The company has a market capitalization of £348.29 million and carries a negative P/E ratio of -5.67 with an unusually high debt-to-equity ratio of 629.58.YahooIlika, Allergy Therapeutics, Ecora Royalties, EGT, Rockfire Resources, Bradda Head LithiumIlika reports it has become a revenue-generating business with initial royalties expected in its 2027 financial year, and its Goliath battery is attracting defense and e-bike market interest. Several companies, including Allergy Therapeutics, Ecora Royalties, European Green Transition, Rockfire Resources, and Bradda Head Lithium, announced positive financial results and operational updates.ProactiveinvestorsAllergy Therapeutics reports accelerated revenue growth in its second halfAllergy Therapeutics PLC reported accelerated revenue growth in its second half, with H2 revenue expected at £23.6 million, up more than 12% from £21 million a year earlier, compared with 7% growth in the first half. Full-year revenue is forecast at £59.9 million, representing 9% growth over the prior year's £55 million, driven by constant-currency increases of more than 4% in Germany and 12% in Spain. The allergy immunotherapy specialist expects double-digit revenue growth in the year to June 2027, supported by Grassmuno's first full peak treatment season and the completion of Germany's transition away from unregistered products under the TAV programme.